Evidence map›Paper›PMID 35774932›Full record

ArticleOpen forum infectious diseases2022

Reaching Hard-to-Reach People Who Use Drugs: A Community-Based Strategy for the Elimination of Hepatitis C.

Nicolas Nagot, Morgana D'Ottavi, Catherine Quillet, Anne Debellefontaine, Joëlle Castellani, Nicolas Langendorfer, Bertrand Hanslik, Sylvain Guichard, René Baglioni, Vincent Faucherre and 4 more

Open access · goldAbstract read
In one paragraph

Article in Open forum infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Nicolas NagotPathogenesis and Control of Chronic & Emerging Infections, University of Montpellier, Montpellier, France.
Morgana D'OttaviPathogenesis and Control of Chronic & Emerging Infections, University of Montpellier, Montpellier, France.
Catherine QuilletPathogenesis and Control of Chronic & Emerging Infections, University of Montpellier, Montpellier, France.
Anne DebellefontainePathogenesis and Control of Chronic & Emerging Infections, University of Montpellier, Montpellier, France.
Joëlle CastellaniPathogenesis and Control of Chronic & Emerging Infections, University of Montpellier, Montpellier, France.
Nicolas LangendorferDepartment of Addiction Medicine, Montpellier University Hospital, Montpellier, France.
Bertrand HanslikDepartment of Addiction Medicine, Montpellier University Hospital, Montpellier, France.
Sylvain GuichardAssociation of Marginality and Drug Addiction (AMT), Montpellier, France.
René BaglioniDepartment of Addiction Medicine, Montpellier University Hospital, Montpellier, France.
Vincent FaucherreDepartment of Addiction Medicine, Montpellier University Hospital, Montpellier, France.
Edouard TuaillonPathogenesis and Control of Chronic & Emerging Infections, University of Montpellier, Montpellier, France.
Georges-Philippe PageauxDepartment of Hepatology and Gastroenterology, Montpellier University Hospital, Montpellier, France.
Didier LaureillardPathogenesis and Control of Chronic & Emerging Infections, University of Montpellier, Montpellier, France.
Hélène Donnadieu-RigolePathogenesis and Control of Chronic & Emerging Infections, University of Montpellier, Montpellier, France.
Université de Montpellier · FRInserm · FRCentre Hospitalier Universitaire de Montpellier · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Elimination of hepatitis C virus (HCV) among people who use drugs (PWUD) remains a challenge even in countries in which HCV care is provided free of cost. We assessed whether an innovative community-based, respondent-driven sampling (RDS) survey, coupled with HCV screening and immediate treatment, could be efficient to detect and cure current PWUD with chronic HCV in a large city of Southern France. Methods: At a community site with peers, PWUD (cannabis not included) were enrolled after confirmation by a urine drug test. Participants were then screened for hepatitis B virus, HCV, and human immunodeficiency virus and benefited from onsite HCV treatment evaluation and prescription. Peer support was provided during treatment, and a systematic visit was scheduled 12 weeks after the end of treatment. The cost of the intervention was estimated. Results: Five hundred fifty-four participants were enrolled. Most were male (78.8%) with a median age of 39 years (interquartile range, 33-46). Cocaine (73.1%) and heroine (46.8%) were the main drugs consumed. Overall, 32.6% of PWUD ( Conclusions: A community-based RDS survey approach, involving peers, proved efficient and cost-effective to reach and cure PWUD for HCV. This innovative strategy could be key for the final step of HCV elimination.

Indexed as

Costs and cost analysisdrug usershepatitis Cinterventionmass screening

Identifiers

PMID35774932
PMCPMC9239554
OpenAlexW4224066151

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.